Lv4
420 积分 2024-11-21 加入
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial
29天前
已关闭
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis
2个月前
已关闭
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
2个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
2个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
2个月前
已完结
LBA4 Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6)
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
3个月前
已完结
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
3个月前
已完结
皖公网安备34019202002308
